When should hemiarthroplasty for an acute hip fracture be performed in a patient taking rivaroxaban, based on timing of drug clearance and renal function?

Timing of Hemiarthroplasty for Acute Hip Fracture in Patients on Rivaroxaban

For patients with acute hip fracture on rivaroxaban with normal renal function (CrCl ≥50 mL/min), proceed with hemiarthroplasty at 24 hours after the last dose; for those with impaired renal function (CrCl <50 mL/min), delay surgery to 48 hours after the last dose. 1, 2

Surgical Timing Algorithm Based on Renal Function

Patients with CrCl ≥50 mL/min (Normal/Mild Impairment)

• Withhold rivaroxaban 24 hours before surgery (last dose Day -1, surgery Day 0)
• This represents a 2-day total interruption period (1 day before, 1 day after) for high bleeding risk procedures like hip fracture surgery 1, 2
• Rivaroxaban half-life is 5-9 hours in younger adults and 11-13 hours in elderly patients 3
• At 24 hours, approximately 4-5 half-lives have elapsed, achieving >90% drug clearance

Patients with CrCl <50 mL/min (Moderate Impairment)

• Withhold rivaroxaban 48 hours before surgery (last dose Day -2, surgery Day 0)
• Renal impairment significantly increases rivaroxaban exposure by 44-65% 3
• Approximately one-third (36%) of rivaroxaban is excreted unchanged in urine 3
• Extended interruption compensates for prolonged drug clearance

Patients with CrCl <30 mL/min (Severe Impairment)

• Withhold rivaroxaban 72 hours before surgery (last dose Day -3, surgery Day 0)
• These patients have 56% higher systemic exposure compared to normal renal function 3
• The 2024 AHA/ACC guidelines specifically recommend longer interruption periods for severe renal impairment 1

Evidence Supporting Early Surgery

Recent high-quality research demonstrates that expedited surgery within 24 hours is safe when appropriate drug clearance is achieved:

• A 2025 retrospective cohort study (n=250) showed that surgery ≤24 hours from admission in patients on factor Xa inhibitors reduced preoperative blood loss without increasing overall bleeding, transfusion rates, or 90-day complications 4
• A 2023 prospective audit (n=22 DOAC patients) confirmed safety of surgery within 24 hours when CrCl >50 mL/min, with tranexamic acid administration at induction 5
• A 2026 retrospective study found that only 2% of patients with eGFR ≥50 mL/min had plasma DOAC concentrations ≥100 ng/mL at 24 hours, compared to 9.4% with eGFR <50 mL/min 6

Practical Implementation

Preoperative Assessment

1. Calculate creatinine clearance immediately using Cockcroft-Gault equation
2. Document exact timing of last rivaroxaban dose from patient/family/pharmacy records
3. Consider DOAC level measurement if surgery must occur urgently (<24 hours) using anti-factor Xa assay calibrated for rivaroxaban 2

Intraoperative Management

• Administer tranexamic acid 1g at anesthesia induction to mitigate any residual anticoagulant effect 5
• Anticipate modestly increased intraoperative blood loss (mean 500 mL vs 330 mL in non-anticoagulated patients) 5
• Have blood products readily available, though massive transfusion is unlikely

Postoperative Resumption

• Resume rivaroxaban 24-48 hours after surgery once hemostasis is achieved 1
• For high bleeding risk procedures like hip fracture surgery, waiting 48 hours postoperatively is reasonable
• Balance thrombotic risk (hip fracture patients have high VTE risk) against bleeding risk

Critical Pitfalls to Avoid

Do not delay surgery beyond necessary drug clearance times. Each day of surgical delay increases mortality risk in hip fracture patients, and this mortality risk often exceeds bleeding risk. The 2025 study showed the delayed group (24-72 hours) had higher 90-day complication rates (41.5% vs 19.4%) compared to expedited surgery 4.

Do not use standard coagulation tests (PT/INR, aPTT) to assess rivaroxaban levels. These tests are insensitive and unreliable for DOACs 2. If drug level assessment is needed, use rivaroxaban-calibrated anti-factor Xa assay.

Do not automatically extend interruption periods beyond guideline recommendations without specific indication. The PAUSE trial demonstrated that standardized 1-2 day interruption protocols for rivaroxaban resulted in low rates of both thromboembolism (0.37%) and major bleeding (1.85%) 2.

Account for drug interactions and hepatic function. Patients taking CYP3A4 or P-glycoprotein inhibitors may require longer interruption periods regardless of renal function 2.

Special Considerations for Elderly Hip Fracture Patients

Elderly patients (the typical hip fracture population) have:

• Prolonged rivaroxaban half-life (11-13 hours vs 5-9 hours) 3
• Higher likelihood of unrecognized renal impairment
• Greater baseline bleeding risk
• Higher mortality from surgical delay

The 2026 study specifically in geriatric hip fracture patients confirmed that most with preserved renal function achieve safe drug levels by 24 hours, supporting the algorithm above 6.